Last updated: July 24, 2026
Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc., appellate docket 15-2021, is a patent-infringement dispute tied to Teva’s generic development. The case posture, asserted claims, patent numbers, district court outcome, ANDA filing, Paragraph IV basis, and settlement terms are required to produce a complete and accurate litigation analysis, including claim-scope and launch-risk implications.
What is Endo v. Teva 15-2021 about, and which patents were asserted?
Answer: The specific patents, asserted claims, and drug/ANDA linkage are not provided in the input, so a complete litigation summary cannot be produced from available information.
Case identification needed for an infringement summary
A litigation summary for a Hatch-Waxman dispute must anchor on:
- Brand/generic product name and formulation (dosage form, strength, route)
- Orange Book listing(s) and the listed “patent numbers”
- Asserted patent(s) and claim numbers (independent and dependent claim mapping)
- District court case number and court (for docket, claim construction record, and injunction posture)
- Federal Circuit or other appellate jurisdiction and decision date
What happened in district court before the 15-2021 appeal?
Answer: District court findings, claim construction, infringement/noninfringement rulings, and damages or injunctive relief are not provided.
What typically matters in Endo-style Hatch-Waxman litigation
A complete appellate-focused analysis normally breaks down:
- Claim construction outcomes (Markman record impact on infringement)
- Summary judgment motions (infringement and invalidity)
- Bench or jury findings if applicable
- Prosecution history estoppel impacts
- Obviousness and enablement holdings tied to asserted prior art
- Treatment of inequitable conduct allegations, if any
What claims did the Federal Circuit address in 15-2021?
Answer: The specific issues raised on appeal (claim construction, infringement, invalidity, standard of review) are not provided.
How to structure an appellate analysis (patent litigation lens)
A litigation analysis typically includes:
- Standard of review per issue category
- Whether the appellate decision turned on claim construction or on the evidentiary record
- Any remand instructions that affect scope of enforceability
- Whether invalidity was affirmed and if so on what grounds (anticipation, obviousness, lack of written description, enablement, indefiniteness)
When does exclusivity end for the Endo product in this dispute, and how does the appeal affect generic timing?
Answer: Product identity and Orange Book listing(s) are not provided, so exclusivity timing and launch windows cannot be tied to 15-2021.
Exclusivity and regulatory timing components that drive market exposure
A launch-risk view requires:
- Marketing exclusivity (5-year new chemical entity or 3-year new clinical investigation, if applicable)
- Patent expiry dates for each listed patent
- Any regulatory exclusivity extension (pediatric exclusivity, orphan exclusivity, etc.)
- 30-month stay operation tied to Paragraph IV litigation
- Trigger events (notice, complaint filing date, decision date)
What is the Orange Book status of the Endo-listed patents at issue in 15-2021?
Answer: Orange Book listings and patent numbers are not provided in the input, so status cannot be enumerated.
Orange Book analysis normally includes
- Listed patents, expiration dates, and status (active, expired, withdrawn)
- 505(b)(2) or ANDA linkage and reference product
- Whether the patent was asserted via Paragraph IV
- Whether any listed patents were omitted or found not infringed
How many patents cover the product, and which ones are formulation, method-of-use, or manufacturing patents?
Answer: Patent estate composition cannot be quantified without knowing the drug and Orange Book listings.
How coverage is usually categorized
- Formulation/device delivery patents (composition, polymorph, particle size, solvate/hydrate)
- Method-of-use patents (indication-specific)
- Manufacturing method patents (process controls, crystallization conditions)
- Combination and dosing regimen patents
Which companies besides Teva are potential challengers, and what does this mean for competitive entry risk?
Answer: Competitor landscape cannot be assessed without the specific ANDA product identity and filing set.
Competitive risk factors that are usually compared
- Other ANDA filers with overlapping Paragraph IV certifications
- Settlement alignment across filers
- Court outcomes affecting non-parties (collateral estoppel or persuasive effect varies by posture)
What generic entry risks exist for Teva after this case?
Answer: Launch risk depends on the final appellate posture and whether asserted patents remain enforceable. Those details are not provided.
Risk evaluation requires final disposition facts
- Affirm/Reverse/In part and remand status
- Whether Teva would be blocked until a specific patent expiry
- Whether design-around or non-infringement positions are still viable
- Whether additional patents were asserted in follow-on cases
What patent litigation affects Endo’s enforcement strategy for this product?
Answer: Without the underlying patents and product identity, enforcement impact cannot be mapped.
Enforcement strategy factors usually evaluated
- Whether Endo’s asserted claims were upheld or narrowed
- Whether invalidity findings weaken the broader patent family
- Whether courts construed key claim terms in a way that constrains future assertions
How strong is the patent estate for the Endo product underlying 15-2021?
Answer: Patent strength cannot be scored without the asserted patents, outcomes, and claim scope.
Strength scoring normally uses
- Litigation outcomes per patent and claim
- Claim breadth, time-to-expiry, and dependency structure
- Prior art volatility and known rejections
- Family size and continuation strategy
- Whether patents survive multiple validity attacks
Does the 15-2021 case involve settlement, and what are the licensing or timing terms?
Answer: Settlement terms and licensing structure are not provided.
What to extract from a settlement agreement
- Whether there is an agreed design-around or “at-risk” launch carve-out
- Payment-for-delay terms (if any) and entry date triggers
- Cross-licenses and covenants not to sue
- Patent assignments or dismissals with prejudice and scope limits
Key Takeaways
- A complete litigation summary and analysis for Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA Inc. (15-2021) requires the underlying product, asserted patent numbers, district court record, appellate issues, and disposition.
- Those inputs are not present, so no accurate patent estate mapping, exclusivity timeline, or generic launch-risk assessment can be produced.
FAQs
- What patents are commonly asserted in Endo v. Teva Hatch-Waxman disputes?
- How does a Paragraph IV appeal in the Federal Circuit change generic launch timing?
- What Orange Book fields should be reviewed to map a litigated patent to its expiration date?
- How do claim construction outcomes drive infringement results in ANDA cases?
- What settlement provisions most directly affect “at-risk” entry for Paragraph IV filers?
References
No sources were cited because the provided input does not include the case decision, docket record details, patent numbers, or product identity required for an accurate, citation-backed litigation summary.
